Mulai
Pfizer
Pembelian

Q3 Trade Pfizer

Oleh OssianH
Q3 results for Pfizer were solid, with adjusted earnings and revenue surpassing expectations. The current drop in share price seems excessive and may be driven by liquidity concerns rather than underlying performance issues. The significant decline in expected sales for COVID products is concerning, but overall, the fundamentals appear stable. This drop could present a buying opportunity if it’s mainly a liquidity grab

Catatan
28.8 needs some type of confirmation, whether it's a retest or very strong orders. This level is crucial for assessing the market's next move
Catatan
Small entry now 28.250
Catatan
locked in 50% with a 1.3% gain x40 levrage. Holding rest BOS
Beyond Technical AnalysisChart PatternsFundamental Analysis
OssianH

Pernyataan Penyangkalan

Informasi dan publikasi tidak dimaksudkan untuk menjadi, dan bukan merupakan saran keuangan, investasi, perdagangan, atau rekomendasi lainnya yang diberikan atau didukung oleh TradingView. Baca selengkapnya di Persyaratan Penggunaan.